SMN2 and proximal spinal muscular atrophy: Coherently with the impaired prenatal motor neuron development of severe SMA patients and mouse models9,20, these observations strongly suggest that the intervention time is the primary factor affecting the clinical outcome of SMN-inducing drugs.